Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CFRX NASDAQ:GALT NASDAQ:NCNA NASDAQ:SPRO NASDAQ:TLC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsGALTGalectin Therapeutics$5.13+5.1%$4.58$0.73▼$6.55$312.61M0.85262,512 shs120,867 shsNCNANuCana$4.19+4.2%$4.12$2.78▼$379.62$120K1.5741,956 shs93,391 shsSPROSpero Therapeutics$2.20-2.2%$2.05$0.51▼$3.22$126.62M1.471.13 million shs666,550 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCFRXContraFect0.00%0.00%0.00%0.00%0.00%GALTGalectin Therapeutics-7.92%-5.97%-0.81%+65.99%+86.26%NCNANuCana-4.51%-25.00%+0.25%-62.78%-98.91%SPROSpero Therapeutics-5.06%-9.64%+10.84%-4.26%+77.17%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsGALTGalectin Therapeutics$5.13+5.1%$4.58$0.73▼$6.55$312.61M0.85262,512 shs120,867 shsNCNANuCana$4.19+4.2%$4.12$2.78▼$379.62$120K1.5741,956 shs93,391 shsSPROSpero Therapeutics$2.20-2.2%$2.05$0.51▼$3.22$126.62M1.471.13 million shs666,550 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCFRXContraFect0.00%0.00%0.00%0.00%0.00%GALTGalectin Therapeutics-7.92%-5.97%-0.81%+65.99%+86.26%NCNANuCana-4.51%-25.00%+0.25%-62.78%-98.91%SPROSpero Therapeutics-5.06%-9.64%+10.84%-4.26%+77.17%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCFRXContraFect 0.00N/AN/AN/AGALTGalectin Therapeutics 2.00Hold$6.0016.96% UpsideNCNANuCana 1.00SellN/AN/ASPROSpero Therapeutics 2.17Hold$5.00127.27% UpsideTLCTaiwan Liposome 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CFRX, TLC, GALT, SPRO, and NCNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025SPROSpero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/8/2025GALTGalectin TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NCNANuCanaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SPROSpero TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025SPROSpero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/27/2025GALTGalectin TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NCNANuCanaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SPROSpero TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/14/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCFRXContraFectN/AN/AN/AN/A($19.92) per shareN/AGALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/ANCNANuCanaN/AN/AN/AN/A$267.86 per shareN/ASPROSpero Therapeutics$47.98M2.58N/AN/A$0.85 per share2.59TLCTaiwan Liposome$3.63M81.14N/AN/A$0.83 per share8.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCFRXContraFect-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/AGALTGalectin Therapeutics-$47.05M-$0.64N/AN/AN/AN/AN/A-225.32%11/13/2025 (Estimated)NCNANuCana-$24.28M-$646.16N/AN/AN/AN/A-592.28%-208.68%11/24/2025 (Estimated)SPROSpero Therapeutics-$68.57M-$0.98N/AN/AN/A-110.35%-120.27%-55.61%11/13/2025 (Estimated)TLCTaiwan Liposome-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/ALatest CFRX, TLC, GALT, SPRO, and NCNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025GALTGalectin Therapeutics-$0.11N/AN/AN/AN/AN/A11/13/2025Q3 2025SPROSpero Therapeutics-$0.25N/AN/AN/AN/AN/A8/20/2025Q2 2025NCNANuCana-$2.7456-$0.16+$2.5856-$0.16N/AN/A8/14/2025Q2 2025GALTGalectin Therapeutics-$0.16-$0.12+$0.04-$0.12N/AN/A8/12/2025Q2 2025SPROSpero Therapeutics-$0.38-$0.03+$0.35-$0.03$11.00 million$14.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCFRXContraFectN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCFRXContraFectN/A0.530.53GALTGalectin TherapeuticsN/A1.431.43NCNANuCanaN/A1.581.58SPROSpero TherapeuticsN/A3.973.97TLCTaiwan Liposome0.673.013.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCFRXContraFect7.85%GALTGalectin Therapeutics11.68%NCNANuCana44.00%SPROSpero Therapeutics25.60%TLCTaiwan Liposome0.22%Insider OwnershipCompanyInsider OwnershipCFRXContraFect0.62%GALTGalectin Therapeutics50.10%NCNANuCana31.20%SPROSpero Therapeutics5.50%TLCTaiwan LiposomeN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCFRXContraFect2310.70 million10.64 millionNot OptionableGALTGalectin Therapeutics964.06 million31.97 millionOptionableNCNANuCana3030,00021,000Not OptionableSPROSpero Therapeutics15056.28 million53.18 millionOptionableTLCTaiwan Liposome2,02042.08 millionN/ANot OptionableCFRX, TLC, GALT, SPRO, and NCNA HeadlinesRecent News About These CompaniesHow to watch TLC’s new medical series ‘Dangerously Obese’ premiere for freeOctober 23 at 3:46 AM | syracuse.comSDoctor from TLC's "Dangerously Obese" talks saving lives with bariatric surgery on Coast LiveOctober 23 at 3:46 AM | wtkr.comWThe series premiere of 'Dangerously Obese' airs Wednesday, October 22 at 9pm ET/PT on TLCOctober 23 at 3:46 AM | uk.news.yahoo.comThree Members of Family From TLC’s ‘Meet the Putmans’ Die in Car CrashSeptember 29, 2025 | today.comT3 Beloved TLC reality stars die in tragic crashSeptember 29, 2025 | msn.com3 Members of TLC’s ‘Meet the Putmans’ Family Killed in Car CrashSeptember 29, 2025 | aol.comAMeet the Putmans family members pass away: TLC's reality TV family suffers tragic lossSeptember 29, 2025 | msn.comThree TLC Meet the Putmans Reality Stars Die in Car CrashSeptember 29, 2025 | yahoo.comThe Wyatt Sicks Retain Tag Team Championship At WWE SummerSlam 2025 In Wild TLC MatchAugust 4, 2025 | msn.comWWE HOFer Bully Ray Has Two Words For SummerSlam 2025 TLC Match Stars: Good LuckAugust 4, 2025 | msn.comThe Hardy Boyz Appear At WWE SummerSlam Ahead Of Six-Way TLC MatchAugust 4, 2025 | si.comSTop tag team gets booed at SummerSlam 2025 after winning the TLC Title matchAugust 4, 2025 | sportskeeda.comSWyatt Sicks Pull Down WWE Tag Titles In Crowded TLC Match At SummerSlam 2025 Night 2August 4, 2025 | msn.comUnexpected Chaos Erupts As 12 Wrestlers Pay Homage In TLC MatchAugust 4, 2025 | thesportster.comTWWE SummerSlam 2025 Night 2 Results: Wyatt Sicks Retain in Brutal TLC Match, But Crowd Doesn’t Buy InAugust 4, 2025 | athlonsports.comAWyatt Sicks Retain WWE Tag Team Championships In TLC Match At SummerSlamAugust 3, 2025 | fightful.comFKIOXIA samples next-gen 512Gb TLC BiCS FLASH storage solutionsJuly 29, 2025 | tweaktown.comTUnbelievable TLC Title Match Set for SummerSlam 2025July 26, 2025 | msn.comTrusted care with a personal touch: TLC Pharmacy marks over a decade of serviceJuly 19, 2025 | discovermoosejaw.comDT-Boz Explains How TLC Bought Back The Rights To Their Name Along With The Amount They Paid For Each LetterJuly 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Sprouts, Darden Offer High-Upside Setups for Risk-TakersBy Sam Quirke | September 26, 20253 Reasons to Buy Sprouts Farmers Market Ahead of EarningsBy Sam Quirke | October 12, 2025CFRX, TLC, GALT, SPRO, and NCNA Company DescriptionsContraFect NASDAQ:CFRXContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Galectin Therapeutics NASDAQ:GALT$5.13 +0.25 (+5.12%) Closing price 04:00 PM EasternExtended Trading$5.13 0.00 (0.00%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.NuCana NASDAQ:NCNA$4.19 +0.17 (+4.23%) Closing price 04:00 PM EasternExtended Trading$4.16 -0.03 (-0.60%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Spero Therapeutics NASDAQ:SPRO$2.20 -0.05 (-2.22%) Closing price 04:00 PM EasternExtended Trading$2.22 +0.01 (+0.68%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Taiwan Liposome NASDAQ:TLCTaiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
